iRhythm Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 revenue was $221.6 million, up 14.9% year over year, with Zio Monitor performing ahead of expectations and driving growth across primary care, innovative channels, and international markets.
- Zio AT revenue was roughly flat year over year, below expectations, while new accounts contributed approximately 51% of year-over-year volume growth.
- Gross margin was 74.2%, up 310 basis points year over year; approximately $3 million of tariff refunds contributed roughly 140 basis points.
- Adjusted operating expenses were $138.6 million, compared with $141.4 million in the prior-year period, a decrease of 2%.
- GAAP net loss was $29.9 million, or $0.90 per diluted share, including a $50 million IP litigation settlement charge; adjusted net income was $27.8 million, or $0.82 per diluted share.
- Adjusted EBITDA was $51.2 million, or 23.1% of revenue, an improvement of over 1,100 basis points year over year.
- Free cash flow was negative $11.5 million, including the $50 million litigation settlement payment, and would have been positive $38.5 million excluding that payment.
- The company ended the quarter with $560.7 million in unrestricted cash, cash equivalents, and marketable securities, and obtained a new $300 million revolving credit facility on November 3rd.
- iRhythm closed its Vital Connect acquisition on October 5th, adding an FDA-cleared mobile cardiac telemetry offering with multimodality capabilities and up to 30 days of monitoring service.
- The company no longer plans to submit Zio MCT to the FDA later this year and expects to submit its filing in 2027.
- Management said innovative channels were the company's fastest-growing business during the quarter and that its research supports a defined ambulatory cardiac monitoring eligible universe of more than 27 million patients.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
We'll now hand the conference over to Francis Pruell, Head of Strategic Finance and Investor Relations.
Francis, please go ahead. Thank you, operator, and thank you all for joining iRhythm's third quarter 2026 earnings call.
With me today are Quentin Blackford, iRhythm's President and Chief Executive Officer, and Dan Wilson, our Chief Financial Officer. Before we begin, please note that management will make forward-looking statements within the meaning of federal securities laws under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our intentions, beliefs, and expectations about future events, strategy, competition, products, operating plans, and performance. Forward-looking statements on this call are based on current estimates and assumptions, involve risks and uncertainties, and actual results may differ materially. These statements are made as of today, November 5, 2026, and are time-sensitive. We undertake no obligation to update or revise them, except as required by law.
Accordingly, you should not place undue reliance on these statements. For a discussion of risks and uncertainties, please refer to our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the SEC. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP. Unless otherwise noted, all references to financial measures on this call are presented on a non-GAAP basis. These non-GAAP measures should not be considered in isolation or as a substitute for or superior to GAAP results. Reconciliations to the most directly comparable GAAP measures can be found in our earnings release and the slides accompanying today's call. With that, I'll turn the call over to Quentin.
Good afternoon, everyone, and thank you for joining us for our third quarter earnings call. We are pleased with iRhythm's progress in the quarter, and our results reflect the positive growth trajectory of our business across multiple channels, as well as the meaningful operating leverage we continue to generate as we scale the Zio platform. I'll begin with the key highlights from the quarter and provide updates on our strategic priorities before turning the call over to Dan for a more detailed review of our financial results and outlook. Third quarter revenue was $221.6 million, up nearly 15% year-over-year against our toughest comparison of the year, as we lapped more than 30% growth in the third quarter of 2025. Overall performance was consistent with our guidance, with our core Zio Monitor business again outperforming our expectations.
That monitor business continues to be driven by durable demand and sustained momentum across primary care, innovative channels, and international markets. We continue to expand the cardiac diagnostics market both within traditional cardiology settings and across these under-penetrated opportunities. The strong performance in the core monitor business was offset by Zio AT, where revenue was roughly flat compared to the prior year. I also want to briefly highlight the record operating leverage we delivered during the quarter, reflected in gross margin of 74.2% and adjusted EBITDA margin of 23.1%. These results demonstrate the strength and scalability of our operating model as we continue to grow the business while investing in the strategic initiatives that we believe will support future growth. This balanced approach supports both our long-term profitability and growth ambitions.
Now I'm going to spend some time talking about the strategy we continue to execute to evolve from a leader in ambulatory cardiac monitoring into a broader cardiac and vitals monitoring and intelligence platform. First, I will walk through the opportunities that VitalConnect brings and then provide an update on the Zio MCT program. As a reminder, we closed the VitalConnect acquisition on October 5, well ahead of our prior expectation of closing by year-end. This acquisition is an exciting milestone for iRhythm, as it significantly expands our capabilities and market opportunity. It also immediately adds a complementary FDA-cleared mobile cardiac telemetry offering to our portfolio. VitalConnect's platform can be used to monitor multiple physiological parameters, including ECG, heart rate, respiratory rate, and body temperature, as well as fall detection and the ability to connect additional parameters such as blood pressure and pulse oximetry.
Its platform supports ambulatory, inpatient, remote patient monitoring, and hospital-to-home care, expanding our relevance across the patient journey and creating new opportunities within hospitals and health systems. VitalConnect will serve as our immediate MCT growth platform while also providing important multimodality capabilities. It supports MCT, cardiac event monitoring, extended monitoring, and Holter use cases with up to 30 days of monitoring service, live look-in functionality, and the flexibility to transition between monitoring pathways when clinically appropriate. These capabilities are particularly important because our planned next-generation Zio MCT, as currently designed, would not address every customer requirement, including live look-in, 30-day reporting, and multimodality workflows. We estimate these use cases represent approximately 25% of the MCT market and believe they are likely to grow over time.
VitalConnect provides us immediate access to these opportunities and, together with our Zio platform, will position us to address essentially the full MCT market with complementary solutions. This expanded portfolio also creates opportunities to deepen existing health system relationships, reach new customers, and accelerate our participation in the broader MCT category. Realizing the full potential of VitalConnect requires more than expanding our product portfolio. We are integrating the technology into our customer EHR systems, incorporating VitalConnect's VistaCenter data and live look-in functionality, and enabling multimodality workflows. These capabilities are essential to driving broader adoption, particularly among our existing large integrated health system customers. In parallel, we are preparing the business to scale across supply chain, clinical operations, customer support, technology, quality, and implementation capacity.
The earlier-than-expected transaction close allows us to accelerate commercial training into the first two weeks of November, enabling our teams to begin engaging customers while we continue building the integration and operating infrastructure required for broader adoption. Our focus is squarely on executing a disciplined integration, and our initial progress reinforces our confidence in the significant value and new growth opportunities this acquisition will unlock for iRhythm. Having taken a significant step in broadening our MCT portfolio, we want to provide an updated view today of our go-forward path in this business. I'll start by directly addressing our next-generation Zio MCT program. In short, we have not delivered the way we want to here, and we recognize that this timeline has shifted multiple times. We share in the frustration this has caused, not only for patients eagerly awaiting this program, but for our investors as well.
Our ongoing commitment to you are transparency and clarity. We've evaluated our MCT strategy in light of the newly combined portfolio and how we can grow our presence in the MCT market as soon as possible. With VitalConnect, we immediately have an additional FDA-cleared MCT offering, and integrating this technology will be our near-term priority. As a result, we no longer plan to submit Zio MCT to the FDA later this year. The addition of VitalConnect's capabilities open up what we believe will be a significant immediate growth opportunity, and this decision will allow us to focus on unlocking that value for patients and shareholders while being deliberate in our planning and preparation to, in turn, maximize the value of our planned next-generation Zio MCT, our integrated MCT portfolio, and your investment.
That said, we've made tangible progress with Zio MCT that gives us greater visibility into the path ahead. We've begun producing and testing the actual Zio MCT system in the configuration we intend to submit to the FDA, and we are advancing the remaining verification, documentation, and regulatory work. We expect to submit our Zio MCT filing to the FDA in 2027. Zio MCT is an important part of our long-term portfolio, as it is designed to build upon the simplicity patients and physicians value in Zio AT by providing an extended wear period and enhanced detection algorithms. We believe that an MCT portfolio today of Zio AT and VitalConnect give us an immediate best-in-class mobile cardiac telemetry portfolio that will further improve with the future introduction of Zio MCT, which we expect will eventually replace Zio AT.
Turning next to Zio AT, we remain confident in its clinical value and the complementary set of solutions it creates with VitalConnect. In August, we published results from the CAMELOT-ALERT study in the American Heart Journal, evaluating nearly 450,000 Medicare beneficiaries across Zio AT, competing MCT platforms, and ambulatory event monitors. The study found that Zio AT delivered significantly higher diagnostic yield than both comparison groups, reinforcing the importance of platform capabilities and clinical workflows in driving diagnostic performance. That said, Zio AT performance was below our expectations during the quarter, where revenue was flat compared to the prior year versus our expectations of growth generally in line with our overall business.
Based on customer and commercial feedback, we believe this was in part driven by delayed purchasing decisions following the announcement of the VitalConnect acquisition as they considered the combined portfolio and the potential availability of VitalConnect through the iRhythm sales channel. We expect these dynamics to persist in the near term, and we will be training our commercial team over the next few months on engaging with customers to sell the full portfolio. This further reinforces the importance of moving quickly to integrate VitalConnect and establish a comprehensive MCT offering that addresses a broader range of customer needs. Our near-term priorities for MCT are clear: successfully integrate the VitalConnect team and business into iRhythm, actively commercialize VitalConnect in the MCT market, thoughtfully expand into adjacent multi-vital opportunities, and continuing advancing Zio MCT through the regulatory process.
We believe our VitalPatch and Zio AT portfolio provides a strong foundation to participate more broadly in the MCT market in the near term, with Zio MCT remaining an important addition to the portfolio over time. Turning to innovative channels and primary care, we continue to see encouraging momentum as we expand cardiac monitoring beyond traditional cardiology settings. What is becoming clearer is that the market opportunity ahead of us is not simply about taking market share. It is about expanding our serviceable market in a meaningful way. More specifically, there is a measurable care gap for patients at risk of arrhythmias that can be addressed through better patient identification, better clinical workflow, and better access. Our research and analysis continue to support that there are more than 27 million patients in a defined ambulatory cardiac monitoring-eligible universe, creating a significant white space of opportunity.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
